| Date Filed | Type | Description |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
SC 13G/A
| BlackRock Inc. reports a 4.6% stake in Immuneering Corp |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/24/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/24/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/19/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/18/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
4
| Brakewood Harold Eugene (Chief Business Officer) has filed a Form 4 on Immuneering Corp|
Txns:
| Granted 165,000 options
@ $9.71, valued at
$1.6M
|
|
| 04/03/2023 |
3
| Brakewood Harold Eugene (Chief Business Officer) has filed a Form 3 on Immuneering Corp |
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
8-K
| Investor presentation, Quarterly results |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8.7% stake in Immuneering Corporation |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 13.7% stake in IMMUNEERING CORP - CLASS A |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/27/2022 |
4
| Zeskind Benjamin J. (PRESIDENT AND CEO) has filed a Form 4 on Immuneering Corp|
Txns:
| Exercised 2,500 options
@ $3.01, valued at
$7.5k
|
|
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/20/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 09/19/2022 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/22/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/12/2022 |
4
| Morales Mallory (VICE PRESIDENT, FINANCE) has filed a Form 4 on Immuneering Corp|
Txns:
| Granted 10,000 options
@ $6.33, valued at
$63.3k
|
|
| 08/11/2022 |
3
| Morales Mallory (Vice President, Finance) has filed a Form 3 on Immuneering Corp |
| 08/10/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/10/2022 |
8-K
| Quarterly results |
| 07/25/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|